Medtronic plc announced that Laura Mauri, M.D., M.S.c. has been appointed Medtronic Chief Scientific, Medical and Regulatory Officer. This appointment adds to Dr. Mauri's prior responsibilities as chief clinical and regulatory officer, aligning and integrating the company's scientific, medical, clinical research and regulatory affairs under her leadership. It leverages her deep expertise and understanding of the interaction between patients and medical technology to accelerate innovation that puts patients first.

Dr. Mauri will also continue to serve as a member of the Medtronic Executive Committee. Priorities for Dr. Mauri include delivering a transformative approach to both patient safety and patient engagement. She recently hired Olaf Hedrich, M.D., B.Ch., a patient safety, risk and analytics industry expert to serve as the company's Chief Medical Safety Officer, responsible for leading an independent medical safety organization that will provide expert input to assure patients safety and quality across Medtronic products.

She will also lead the integration of robust and independent medical expertise into the company's business processes, including investment decisions, business development, exploration of therapeutic areas and development of novel technologies. Dr. Mauri joined Medtronic in September 2018 and became a member of the company's Executive Committee in August 2020. Dr. Mauri succeeds Richard Kuntz, M.D., M.S.c. as Chief Medical and Scientific Officer, who previously announced his retirement, effective April 29, 2022.